Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
University of Rochester NCORP Research Base
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03367572
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.
Intervention
Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment
Condition
Breast Carcinoma
Investigators
Luke Peppone, Bryan A. Faller, Brian L. Burnette, Site Public Contact, Mary Ontko, Eileen Mederos, RN, Kamara Mertz-Rivera, Connie Szczepanek, RN, Amy Koffarnus, Neha Glandt, Kristina Gardner, Heather Albertson, Sheree Oxley, Kin Williams, Sarah Smith, Susan Tuttle, Karen Sartell, Kate Bryant-Greenwood, Debbie Kettner-Sieber, Jenna Russell